Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NPCE NASDAQ:RXST NASDAQ:SNWV NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNPCENeuroPace$9.06-0.2%$12.33$5.45▼$18.98$297.15M1.93188,032 shs132,242 shsRXSTRxSight$7.35-0.4%$13.32$6.32▼$58.23$298.68M1.21819,912 shs1.25 million shsSNWVSanuwave Health$39.24+4.9%$31.55$5.17▼$39.83$336.26M1.24118,287 shs111,101 shsTELATELA Bio$2.13+7.6%$1.69$0.86▼$4.78$84.25M0.9203,859 shs64,032 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNPCENeuroPace0.00%-4.83%-14.53%-16.03%+20.64%RXSTRxSight0.00%-8.13%-47.01%-49.06%-84.43%SNWVSanuwave Health0.00%+12.82%+18.91%+30.89%+3,923,999,900.00%TELATELA Bio0.00%+6.50%+27.54%+122.76%-54.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNPCENeuroPace2.9629 of 5 stars3.53.00.00.00.64.20.6RXSTRxSight2.3397 of 5 stars4.01.00.00.01.61.70.6SNWVSanuwave HealthN/AN/AN/AN/AN/AN/AN/AN/ATELATELA Bio2.2226 of 5 stars3.44.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNPCENeuroPace 3.00Buy$17.0087.64% UpsideRXSTRxSight 1.91Reduce$17.50138.10% UpsideSNWVSanuwave Health 0.00N/AN/AN/ATELATELA Bio 2.75Moderate Buy$7.25240.38% UpsideCurrent Analyst Ratings BreakdownLatest TELA, RXST, NPCE, and SNWV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025RXSTRxSightMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.007/10/2025RXSTRxSightJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $9.007/9/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.007/9/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.007/9/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $9.007/9/2025RXSTRxSightOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/9/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.007/9/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.007/9/2025RXSTRxSightBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNPCENeuroPace$79.91M3.72N/AN/A$0.27 per share33.56RXSTRxSight$139.93M2.13N/AN/A$6.98 per share1.05SNWVSanuwave Health$32.63M10.31N/AN/A($1.49) per share-26.34TELATELA Bio$69.30M1.22N/AN/A$0.72 per share2.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)RXSTRxSight-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/7/2025 (Estimated)SNWVSanuwave Health-$31.37M-$4.56N/A∞N/A-89.86%N/A-145.76%N/ATELATELA Bio-$37.84M-$1.41N/AN/AN/A-61.00%-402.45%-62.73%8/11/2025 (Estimated)Latest TELA, RXST, NPCE, and SNWV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A8/11/2025Q2 2025TELATELA Bio-$0.18N/AN/AN/A$20.67 millionN/A8/7/2025Guidance UpdateRXSTRxSight-$0.0363N/AN/AN/A$39.78 millionN/A5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/9/2025Q1 2025SNWVSanuwave HealthN/A-$0.66N/A-$0.66N/A$9.34 million5/8/2025Q1 2025TELATELA Bio-$0.21-$0.25-$0.04-$0.25$17.35 million$18.52 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNPCENeuroPaceN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNPCENeuroPace2.466.635.70RXSTRxSightN/A12.6811.65SNWVSanuwave HealthN/A0.400.28TELATELA Bio2.284.223.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNPCENeuroPace78.83%RXSTRxSight78.78%SNWVSanuwave Health42.53%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipNPCENeuroPace20.50%RXSTRxSight9.57%SNWVSanuwave Health14.90%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNPCENeuroPace17032.80 million26.08 millionOptionableRXSTRxSight22040.64 million36.75 millionOptionableSNWVSanuwave Health408.57 million7.29 millionN/ATELATELA Bio12039.56 million37.70 millionOptionableTELA, RXST, NPCE, and SNWV HeadlinesRecent News About These CompaniesTELA Bio, Inc. (TELA) Latest Stock News & Headlines - Yahoo FinanceJuly 19 at 4:56 PM | finance.yahoo.comTELA Bio (NASDAQ:TELA) Shares Down 5.4% - Here's What HappenedJuly 8, 2025 | marketbeat.comBreakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)July 3, 2025 | finance.yahoo.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comTELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deTELA Bio, Inc. Grants Inducement Equity Awards to New Senior Vice President Jim HagenJune 6, 2025 | quiverquant.comQTELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 4, 2025 | tmcnet.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 3, 2025 | globenewswire.comTELA Bio Names Jeffrey Blizard as President to Drive Strategic GrowthJune 3, 2025 | msn.comTELA Bio Appoints Jeffrey Blizard as President to Drive Growth and InnovationJune 2, 2025 | quiverquant.comQTELA Bio Appoints Jeffrey Blizard as PresidentJune 2, 2025 | globenewswire.comTELA Bio to Present at the 2025 Jefferies Global Healthcare ConferenceMay 25, 2025 | msn.comTELA Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comPiper Sandler Sticks to Their Hold Rating for TELA Bio (TELA)May 22, 2025 | theglobeandmail.comTELA Bio Announces Inducement Grants to New Hires with 4-Year Vesting PlanMay 12, 2025 | msn.comTELA Bio Reports Q1 2025 Growth and Product ExpansionMay 12, 2025 | msn.comTELA Bio, Inc. (TELA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comEarnings call transcript: Tela Bio Q1 2025 revenue miss, stock rises 9%May 10, 2025 | uk.investing.comTELA Bio Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finance.yahoo.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTELA, RXST, NPCE, and SNWV Company DescriptionsNeuroPace NASDAQ:NPCE$9.06 -0.02 (-0.22%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$9.12 +0.05 (+0.61%) As of 07/18/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.RxSight NASDAQ:RXST$7.35 -0.03 (-0.41%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.45 +0.10 (+1.31%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Sanuwave Health NASDAQ:SNWV$39.24 +1.82 (+4.86%) As of 07/18/2025 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.TELA Bio NASDAQ:TELA$2.13 +0.15 (+7.58%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.12 0.00 (-0.23%) As of 07/18/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
